Table 1 Effects of immune status on the course of viral infections, outcomes, and therapy
From: Could hemophagocytic lymphohistiocytosis be the core issue of severe COVID-19 cases?
Normal immunity | Immunodeficiency (primary or secondary) | Immune disorder (genetic or acquired) | |
|---|---|---|---|
Response to infection | Correct | Insufficient | Excessive |
Course of viral infection | Infection limitation and subsequent elimination | Disseminated, systemic or chronic viral infection | Disseminated or systemic inflammation (i.e., HLH, CRS) |
Consequences | Recovery | Single or multi-organ failure | Multi-organ failure |
Potential interventions | Vaccinations Antiviral drugs | Vaccinations Antiviral drugs Intravenous immunoglobulins | Immunosuppression |